Results 51 to 60 of about 4,258 (204)

Clinical Spectrum and Outcomes of SOX1 Antibody‐Associated Paraneoplastic Neurological Syndromes: A Chinese Cohort Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background SOX1 antibody‐positive paraneoplastic neurological syndromes (PNS) exhibit significant population‐specific clinical heterogeneity. While Western cohorts predominantly manifest Lambert‐Eaton myasthenic syndrome (65%–80%), comprehensive clinical characterization and treatment response data in Asian populations remain critically ...
Jin‐Long Ye, Zu‐Ying Kuang, Bo Li, Meng‐Qiu Pan, Li‐Hua Zhou, Yang‐Yang Dai, Si‐Fen Xie, Xian‐Guang Lin, Ye‐Peng Hu, Li‐Hong Jiang, Zhan‐Hang Wang, Wei‐Jing Zhang   +11 more
wiley   +1 more source

a pilot study [PDF]

, 2015
Muscular weakness in myasthenia gravis (MG) is commonly assessed using Quantitative Myasthenia Gravis Score (QMG). More objective and quantitative measures may complement the use of clinical scales and might detect subclinical affection of muscles.
Brandt, Alexander U., Hoffmann, Sarah, Kohler, Siegfried, Meisel, Andreas, Paul, Friedemann, Piper, Sophie K., Reilmann, Ralf, Sass, Christian, Siedler, Jana   +8 more
core   +1 more source

Non‐Cyclic Rozanolixizumab Administration in Complex Generalized Myasthenia Gravis

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Rozanolixizumab, an inhibitor of the neonatal Fc receptor (FcRn), is used to treat patients with generalized myasthenia gravis (gMG) refractory to standard therapies. However, the approved six‐week cyclic regimen may be associated with a “wearing‐off” effect and disease fluctuations. We evaluated the non‐cyclic administration
Marc Abi Aoun, Diane Beauvais, Marlène Barnay, Marie‐Hélène Violleau, Stéphane Mathis, Fanny Duval, Guilhem Sole   +6 more
wiley   +1 more source

risk factors and impact on quality of life [PDF]

, 2016
Objectives Emerging evidence suggests that fatigue in myasthenia gravis (MG) is a relevant problem that negatively impacts activities of daily living (ADL). The relationship between fatigue and quality of life (QoL) has never been systematically explored
Grittner, Ulrike, Hoffmann, Sarah, Kohler, Siegfried, Meisel, Andreas, Ramm, Johanna, Siedler, Jana   +5 more
core   +1 more source

Experience Using Efgartigimod to Treat Juvenile Myasthenia Gravis in China: A Multicenter Retrospective Study

Muscle &Nerve, Volume 73, Issue 6, Page 1025-1031, June 2026.
ABSTRACT Introduction/Aims Current therapeutic management of juvenile myasthenia gravis (JMG) predominantly relies on conventional immunosuppressive therapies and expert consensus extrapolated from adult data, creating a critical gap in high‐quality, pediatric‐specific clinical evidence.
Jing Lin, Guoyan Qi, Susan Luo, Qilong Jiang, Bitao Bu, Min Liu, Yuzhen Wei, Meigui Han, Junhong Yang, Zhilan Zhao, Lili Zhang, Yifan Zhang, Haoyou Xu, Xingjie Hao, Zhijun Li   +14 more
wiley   +1 more source

Long-term safety and efficacy of eculizumab in generalized myasthenia gravis [PDF]

, 2019
Introduction: Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of an open-label extension of REGAIN,
Andersen, Henning, Barohn, Richard J, Benatar, Michael, Burns, Ted M, Casasnovas, Carlos, De Bleecker, Jan, Fujita, Kenji P, Howard, James F, Jr., Illa, Isabel, Jacob, Saiju, Kissel, John T, Mantegazza, Renato, Muppidi, Srikanth, Murai, Hiroyuki, Nowak, Richard J, O'Brien, Fanny L, Utsugisawa, Kimiaki, Vissing, John, Vu, Tuan H, Wang, Jing Jing   +19 more
core   +2 more sources

Chimeric Antigen Receptor T‐Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions

Muscle &Nerve, Volume 73, Issue 6, Page 942-951, June 2026.
ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Tobias Hegelmaier, Alexander Duscha, Christiane Desel, Sarah Stassen, Tim Krzemien, Ann‐Katrin Hennemann, Vaia Pappa, Aiden Haghikia   +7 more
wiley   +1 more source

Successful Treatment of Immune Checkpoint Inhibitor‐Induced Myocarditis, Myositis, and Myasthenia Overlap Syndrome With Baricitinib and Abatacept

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Immune checkpoint inhibitor (ICI) therapies are known to cause immune‐related adverse events (irAEs), including life‐threatening myocarditis, myositis, and myasthenia (MMM) overlap syndrome. Current literature lacks established therapeutic guidelines for effective management with steroid‐sparing agents.
Zeinab Alnahas, Sujata Sarkar, Oishi Roychoudhury, Ernest Algabre   +3 more
wiley   +1 more source

Emotional stress as a trigger of myasthenic crisis and concomitant takotsubo cardiomyopathy: a case report

Journal of Medical Case Reports, 2010
Introduction Myasthenia gravis is a neuromuscular junction post-synaptic autoimmune disorder. Myasthenic crisis is characterized by respiratory failure requiring mechanical ventilation.
Levine Reed, Wang JingTian, Beydoun Said R, Farvid Ali   +3 more
doaj   +1 more source

An update on myasthenia gravis [PDF]

, 2000
Myasthenia gravis (MG) is an autoimmune disease characterised by autoantibodies against acetylcholine receptors at neuromuscular junctions, resulting in defective neuromuscular transmission.
Chan, KH, Ho, SL
core